Đánh giá hiệu quả của Gefitinib trên bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn tái phát, di căn ở Bệnh viện Hữu Nghị Việt Tiệp=Evaluation of the effectiveness of Gefitinib in patients with recurrent and metastatic non-small cell lung cancer at Viet Tiep Friendship Hospital

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Bích Ngọc Đặng, Thị Hà Đỗ, Văn Tú Hoàng, Thị Thu Hường Lê, Quang Hưng Trần, Thị Nga Vũ

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2024

Mô tả vật lý: tr.129-135

Bộ sưu tập: Metadata

ID: 245912

Thêm vào giỏ

Đánh giá hiệu quả điều trị và nhận xét một số độc tính của thuốc Gefitinib trên bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn tái phát, di căn. Đối tượng và phương pháp nghiên cứu: nghiên cứu hồi cứu mô tả trên 42 bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn tái phát, di căn được điều trị bằng thuốc Gefitinib tại Trung tâm UB-YHHN, Bệnh viện Hữu Nghị Việt Tiệp từ 1/1/2022 đến 31/12/2023. Kết quả: Thời gian xuất hiện đáp ứng điều trị là 2.5 ± 1 tuần.Tỷ lệ cải thiện triệu chứng đau ngực 90.6%, ho 91.4%, khó thở 83.3%.Tỷ lệ đáp ứng hoàn toàn là 2.4%, đáp ứng một phần là 64.3%.Độc tính của thuốc: thuốc dung nạp tốt, độc tính chủ yếu là nổi ban, hạ Hemoglobin, ít có độc tính trên gan, thận.Không có trường hợp nào phải ngưng điều trị do độc tính của thuốc. Kết luận: Gefitinib giúp cải thiện đáng kể tỷ lệ đáp ứng và dung nạp tốt ở bệnh nhân UTPKTBN giai đoạn tái phát, di căn.To evaluate the treatment efficacy and comment on some toxicities of Gefitinib in patients with recurrent and metastatic non-small cell lung cancer. Subjects and methods: A retrospective study describing 42 patients with recurrent and metastatic non-small cell lung cancer treated with Gefitinib at the Center for Oncology and Oncology, Viet Tiep Friendship Hospital from January 1, 2022 to December 31, 2023. Results: The time to appear the response to treatment was 2.5 ± 1 week. The rate of improvement in chest pain symptoms was 90.6%, cough 91.4%, shortness of breath 83.3%. The rate of complete response was 2.4%, partial response was 64.3%. Drug toxicity: the drug was well tolerated, the main toxicity was rash, low hemoglobin, little toxicity on liver and kidney. There were no cases of discontinuation of treatment due to drug toxicity. Conclusion: Gefitinib significantly improved the response rate and good tolerance in patients with recurrent and metastatic NSCLC.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR